banner news

Taiwan, January 14, 2022--SARS-CoV-2, Influenza virus, and Respiratory syncytial virus (RSV) are the well-known pathogens responsible for several contagious respiratory diseases, which can cause mild to severe illness and even death. These pathogens can spread very quickly from person to person, simply by touching or breathing in virus-containing particles. A case in point is COVID-19, it has been the most prevailing contagion worldwide since late 2019. To identify the disease, billions of specimens have been collected by the frontline healthcare operators every day to perform the respective diagnostic tests. Therefore,  it is crucial to implement appropriate measures to reduce the risk of virus exposure and protect the healthcare operators carrying out the tests

 

In a study published in Nature Scientific Reports1, our VitaPCR™ Sample Collection Buffer was shown to effectively inactivate SARS-CoV-2 virus. In another inactivation study done by an external laboratory, treatment with the VitaPCR™ Sample Collection Buffer for 1 minute is capable of reducing Influenza A Virus, Influenza B Virus, and RSV titer by ≥ 4 log10 PFU/mL. Therefore, as the first step in our tests2 procedures, by mixing the patients’ swabs into our VitaPCR™ Sample Collection Buffer, the risk of virus exposure on testing operators is greatly reduced and therefore their safety is not compromised.  

 

As a leader in the development of advanced medtech diagnostics solutions, Credo Diagnostics is proud to announce that we have dedicated ourselves to not only providing excellent and accurate diagnostic solutions, what we have designed ensures that the operators in the front line are safe – truly in line with our mission of improving the lives of those we love. With the inactivation effectiveness on SARS-CoV-2 Virus, Influenza A Virus, Influenza B Virus, and RSV, there is no doubt our VitaPCR™ Sample Collection Buffer is one of the ideal tools in our VitaPCR™ solution.

 

For more information, please contact us at service@credodxbiomed.com

 

1.Davies, K., Arnold, U., Buczkowski, H. et al.Virucidal efficacy of guanidine-free inactivants and rapid test buffers against SARS-CoV-2. Sci Rep11, 23379 (2021). https://doi.org/10.1038/s41598-021-02942-4

2. The VitaPCR™ Sample Collection Buffer is provided in VitaPCR™ SARS-CoV-2 Gen 2 Assay, VitaPCR™ Flu A&B Assay, VitaPCR™ Influenza/SARS-CoV-2 (Flu/SC2) Assay, and VitaPCR™ Flu/RSV Assay


 

About Credo Diagnostics Biomedical Pte. Ltd.

Credo Diagnostics develops and manufactures innovative, easy-to-use and rapid molecular diagnostic solutions for Point-of-Care (POC) applications at affordable costs without compromising accuracy and speed in the areas Human Health. Leveraging solid and established science, combined with efficient integration and strategic innovation, Credo Diagnostics Biomedical provides advanced medical technologies for all.

CONTACT

We at Credo Diagnostics pioneer accessible diagnostic platforms to improve the lives of those we love. We believe providing the right information to the right people at the right time leads to better outcomes.